Serial Entrepreneur and Billionaire Ben Lamm’s Colossal Biosciences Secures $200 Million in Series C Funding

Dallas-based biotechnology company Colossal Biosciences has made waves in the scientific community by securing $200 million in Series C funding, bringing its valuation to an impressive $10.2 billion. This latest round of investment marks a significant milestone for the company, which has now raised a total of $435 million since its inception in 2021.

Reviving the Extinct: Colossal’s Mission

Serial Entrepreneur and billionaire Ben Lamm’s Colossal Biosciences has set out to achieve what many thought impossible: the resurrection of extinct species. Leveraging groundbreaking genetic engineering techniques, the company aims to reintroduce species such as the woolly mammoth, the Tasmanian tiger, and the dodo into their natural habitats. These efforts are not merely about recreating the past; they hold the potential to address modern ecological challenges.

The company’s most notable project involves integrating preserved woolly mammoth DNA into the genome of the Asian elephant, its closest living relative. The resulting hybrid species is designed to be cold-resistant, enabling it to thrive in Arctic environments and contribute to ecosystem restoration. Similarly, Colossal is working on reconstructing the genome of the Tasmanian tiger and other extinct species, utilizing advanced CRISPR gene-editing technology to make these ambitious plans a reality.

A Bold Vision Backed by Science

Colossal’s innovative approach combines de-extinction science with ecological restoration. The company believes that bringing back species like the woolly mammoth could mitigate climate change by altering ecosystems in ways that reduce carbon emissions. For instance, mammoths could help convert Arctic tundra back into grasslands, which are more efficient at sequestering carbon.

“Our mission goes beyond just reviving extinct species,” said Ben Lamm, co-founder and CEO of Colossal Biosciences. “We aim to create practical solutions to some of the biggest environmental challenges of our time.”

Significant Backing and Scientific Breakthroughs

The Series C funding will allow Colossal to accelerate its research and expand its team of leading geneticists, conservationists, and ecologists. The investment also underscores growing confidence in the company’s vision and scientific capabilities. Investors see the potential for Colossal’s technology to pioneer new applications in genetic science, ranging from biodiversity preservation to combating diseases.

Colossal has already achieved several groundbreaking milestones, including the reconstruction of highly accurate genomes for multiple extinct species. These advancements set the stage for further progress as the company moves closer to creating viable de-extinct hybrids and reintroducing them into the wild.

What’s Next for Colossal?

Looking ahead, Colossal plans to focus on scaling its operations and preparing for the eventual reintroduction of its hybrid species. While challenges remain—including ethical concerns and ecological implications—the company is committed to working with conservationists and governments to ensure responsible and sustainable outcomes.

Colossal’s journey represents a fascinating blend of science fiction and reality, capturing the imagination of the public while addressing pressing environmental issues. With its bold vision and robust funding, the company is well-positioned to lead the charge in the emerging field of de-extinction science.

As Colossal pushes the boundaries of what’s possible, it also raises profound questions about humanity’s role in shaping the natural world. Whether the return of the woolly mammoth and other extinct species will transform our planet for the better remains to be seen, but one thing is certain: Colossal Biosciences is making history.